PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER
The purpose of this study is to compare the effects, good and/or bad, of adding either prostate removal surgery or radiation therapy to standard systemic therapy (SST), which is used to treat prostate cancer.
- IRB Number: 1905016643 (S1802)
- Research Study Identifier: TX10448
- Principal Investigator: Nabil Adra, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required